Treatment of Pulmonary Hypertension
Immediate Diagnostic Imperative Before Any Treatment
All patients with suspected pulmonary hypertension must undergo right-heart catheterization at an expert PH center before initiating any PAH-specific therapy. 1, 2, 3
- Right-heart catheterization is mandatory to confirm PH (mean PAP > 20 mmHg, PCWP ≤ 15 mmHg, PVR ≥ 3 Wood units) and establish the correct WHO classification, as treatment differs fundamentally between groups. 2, 3
- Critical pitfall: Starting PAH-specific drugs empirically without proper classification can delay appropriate treatment and cause harm, particularly in Group 2 PH (left heart disease) where these medications are contraindicated. 3
- Acute vasoreactivity testing with inhaled nitric oxide, IV epoprostenol, or adenosine must be performed during catheterization to identify the ~10% of patients eligible for calcium-channel blocker therapy. 1, 2
Risk Stratification Framework
Comprehensive severity assessment using multiple parameters determines treatment intensity and guides all therapeutic decisions. 1, 2
Key parameters to assess at baseline and every 3–6 months: 2
- WHO functional class (target: I–II)
- 6-minute walk distance (target: >440–500 m)
- BNP/NT-proBNP levels (target: <50 ng/L)
- Echocardiographic findings (right atrial size, pericardial effusion, TAPSE)
- Hemodynamics (right atrial pressure <8 mmHg, cardiac index >2.5 L/min/m²)
The therapeutic goal is achieving and maintaining low-risk status across all domains; intermediate-risk status is inadequate and mandates treatment escalation. 2
Treatment Algorithm by Vasoreactivity and Functional Class
Vasoreactive Patients (~10% of Idiopathic PAH)
High-dose calcium-channel blockers are first-line therapy for patients with positive acute vasoreactivity testing. 1, 2
- Positive response defined as: ≥10 mmHg fall in mean PAP to <40 mmHg with stable or increased cardiac output. 2
- Preferred agents: long-acting nifedipine 120–240 mg daily, diltiazem 240–720 mg daily, or amlodipine up to 20 mg daily. 1, 2
- Avoid verapamil due to negative inotropic effects. 1
- Critical monitoring: If patients do not improve to WHO FC I–II within 3–6 months, transition immediately to PAH-specific combination therapy. 1, 2
- Pitfall: Never use calcium-channel blockers in non-vasoreactive patients—they can precipitate severe hypotension and right heart failure. 2
Non-Vasoreactive Patients: WHO Functional Class I (Asymptomatic)
Monitor every 3–6 months without initiating PAH-specific pharmacotherapy. 2
- No approved therapy has demonstrated benefit in asymptomatic patients. 2
- Reassess at each visit for progression to symptomatic disease. 2
Non-Vasoreactive Patients: WHO Functional Class II–III (Low to Intermediate Risk)
Initial oral combination therapy with ambrisentan plus tadalafil is the recommended first-line treatment. 1, 2
- This dual-pathway regimen (endothelin receptor antagonist + phosphodiesterase-5 inhibitor) delays clinical failure and improves outcomes compared with monotherapy. 1, 2
- Rationale: Targets two distinct pathogenic pathways simultaneously, providing superior efficacy. 2
Alternative monotherapy options (only if combination not tolerated): 2
- Endothelin receptor antagonists: bosentan, macitentan, or ambrisentan
- Phosphodiesterase-5 inhibitors: sildenafil or tadalafil
- Soluble guanylate cyclase stimulator: riociguat (improves 6-minute walk distance by ~36 m and reduces PVR by ~223 dyn·s·cm⁻⁵)
Absolute contraindication: Never combine riociguat with PDE-5 inhibitors due to severe hypotension risk. 1, 2
Non-Vasoreactive Patients: WHO Functional Class III–IV (High Risk)
Initial combination therapy including continuous intravenous epoprostenol should be prioritized—it is the only therapy proven to reduce 3-month mortality in high-risk PAH patients. 1, 2
- IV epoprostenol is the gold-standard therapy for WHO FC IV patients and provides the greatest survival advantage in prospective randomized trials. 1, 2
- Alternative prostacyclin options (IV treprostinil, subcutaneous treprostinil, inhaled iloprost) may be used but have less robust mortality data. 2
- For WHO FC III patients with rapid progression: Consider upfront triple therapy including IV prostacyclin. 1
Sequential Treatment Escalation for Inadequate Response
Patients who remain symptomatic or deteriorate on initial therapy require sequential addition of drugs targeting different pathways. 2
Escalation strategy: 2
- On monotherapy → Add second drug class from a different pathway
- On dual oral therapy → Add prostacyclin-pathway agent:
- Inhaled treprostinil (improves 6-minute walk distance by median ~16 m)
- Subcutaneous or IV treprostinil (reduces mean PAP by 22.3 mmHg vs 10.7 mmHg with placebo)
- IV epoprostenol for severe cases
- On dual therapy without adequate response → Attempt triple combination therapy before considering transplant
Critical timing: Do not delay escalation—intermediate-risk status mandates intensification. 2
Essential Supportive Measures
Diuretics and Oxygen
Loop diuretics are indicated for all PAH patients with signs of right ventricular failure and fluid retention (peripheral edema, elevated JVP, ascites). 1, 2, 3
- Monitor electrolytes, renal function, and daily weights during active diuresis. 3
**Continuous long-term oxygen therapy is indicated when arterial PO₂ is consistently <60 mmHg (8 kPa)** to maintain saturations >90%. 1, 2
- In-flight oxygen should be provided to WHO FC III–IV patients. 2
Anticoagulation
Oral anticoagulation (target INR 1.5–2.5 in North America, 2.0–3.0 in Europe) should be considered for idiopathic PAH, heritable PAH, and anorexigen-induced PAH. 1, 2
- Evidence is weaker for associated PAH (connective tissue disease, congenital heart disease) but may still be considered. 2
General Measures
Pregnancy must be avoided in all PAH patients due to 30–50% maternal mortality risk. 1, 2
- If pregnancy occurs, management must be at a specialized PAH center. 2
Immunization against influenza and pneumococcal infection is recommended. 1, 2
Supervised exercise rehabilitation should be considered for deconditioned patients as it improves exercise capacity and quality of life. 1, 2
- Excessive physical activity provoking distressing symptoms should be avoided. 2
Epidural anesthesia is preferred over general anesthesia for elective surgery when feasible. 2
Psychosocial support is essential given the substantial emotional and financial burden. 2
Advanced and Rescue Therapies
Lung Transplantation
Eligibility for lung transplantation should be considered promptly after inadequate clinical response to maximal medical therapy. 1, 2
- Do not delay referral to transplant centers when patients show inadequate response to combination therapy. 2
Balloon Atrial Septostomy
May be considered as a palliative or bridging procedure in patients deteriorating despite maximal medical therapy. 1, 2
Treatment for Other PH Groups (Non-PAH)
Group 2: PH Due to Left Heart Disease
Treatment should focus on optimizing the underlying cardiac condition; PAH-specific therapies are not recommended and may be harmful. 1, 3
Group 4: Chronic Thromboembolic PH (CTEPH)
Pulmonary endarterectomy is the treatment of choice when feasible. 1, 3
- For inoperable CTEPH, riociguat has proven efficacy. 4
Critical Pitfalls to Avoid
- Never start PAH-specific drugs without right-heart catheterization and proper classification. 3
- Never combine riociguat with PDE-5 inhibitors—this is absolutely contraindicated. 1, 2
- Never use calcium-channel blockers in non-vasoreactive patients—they cause severe hypotension and right heart failure. 2
- Never delay escalation to IV prostacyclin in high-risk or rapidly deteriorating patients—early initiation improves survival. 2
- Never delay referral to a specialized PAH center—accurate diagnosis and optimal drug selection require expert expertise. 2, 3
- Never rely on monotherapy for most patients—current evidence strongly supports initial combination therapy. 2
Monitoring Schedule and Reassessment Triggers
Reassess at baseline, every 3–6 months in stable patients, whenever therapy is initiated or changed, and at any sign of clinical worsening. 2